Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
26. Juli 2021 02:30 ET
|
Allarity Therapeutics A/S
Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program Press release Hørsholm, Denmark and...